Antibiotic injection for the treatment of bacterial skin, and urinary tract infections.
Reconstituted product: Use the contents within 56 days of first broaching the vial. Store refrigerated in original carton and discard the unused portion.
AVET Cefovecin Sodium Lyophilised Powder for Injection is to be administered as a single subcutaneous injection at a dosage of 1 mL/10 kg bodyweight (8 mg/kg). A single injection provides a full 14-day course of therapy.
When indicated, for skin infections in dogs, a second subcutaneous injection can be administered 14 days after the first dose to provide therapeutic levels for a total of 28 days.
Factors to be considered in the determination of an additional dose are the nature and severity of the infection, the susceptibility of the pathogen, and the immune status of the animal. Susceptibility of bacterial pathogens should be determined prior to treatment. Therapy with AVET Cefovecin Sodium Lyophilised Powder for Injection may be initiated before the results of these tests are known. If acceptable response to treatment is not observed, then the diagnosis should be re-evaluated and appropriate alternative therapy considered.
A single injection is indicated for severe infections of the gingival and periodontal tissues in dogs as an adjunct to mechanical or surgical periodontal surgery.
Preparation of solution for injection: To deliver the appropriate dose, reconstitute the Lyophilised Powder with 10 mL Sterile Water for Injection. Shake and/or allow vial to sit until all material is dissolved.
CEFOVECIN (AS SODIUM SALT)
For use by or under direction of a veterinarian.
Antibiotic injection for the treatment of bacterial skin, and urinary tract infections sensitive to cefovecin in dogs and cats and for the treatment of severe infections of gingival and periodontal tissues associated with Porphyromonas spp. and Prevotella spp in dogs.
AVET Cefovecin Sodium Lyophilised Powder for Injection (cefovecin) is indicated for the treatment of bacterial infections sensitive to cefovecin in dogs and cats with the following conditions:
DOGS
Skin infections including bacterial folliculitis, wounds, and abscesses caused by susceptible strains of Staphylococcus intermedius, Streptococcus canis (Group G, β haemolytic), Escherichia coli and Proteus mirabilis.
Urinary tract infections (cystitis) associated with susceptible strains of Escherichia coli, Proteus mirabilis and Staphylococcus intermedius.
As adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of gingival and periodontal tissues associated with Porphyromonas spp. and Prevotella spp.
CATS
Skin infections including abscesses and wounds caused by susceptible strains of Pasteurella multocida, Streptococcus canis (Group G, β haemolytic), and Staphylococcus intermedius.
Urinary tract infections associated with susceptible strains of Escherichia coli.
Indiscriminate use of cefovecin (cephalosporin) may contribute to the development of antibiotic resistance.
Not to be used in dogs or cats with a known allergy to cephalosporins. Cefovecin should be used with caution in penicillin-allergic animals.
Before we can share our Therapeutic range, please confirm that you are a veterinarian.